Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | GAA | P10253 | 4/20 | 0.70 |
| ▸ | THRB | P10828 | 3/20 | 0.70 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.70 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | YWHAG | P61981 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RAD52 | P43351 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429632 | 0.85 | MAPT (0.62) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL6156455 | 0.84 | ALDH1A1 (0.96) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL923404 | 0.83 | MAPT (0.62) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL241271 | 0.82 | ALDH1A1 (0.93) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL7031588 | 0.80 | ALDH1A1 (0.89) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL3162979 | 0.79 | SLC18A3 (0.57) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL28770706 | 0.79 | ALDH1A1 (0.71) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL6272228 | 0.78 | ALDH1A1 (0.86) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL28147210 | 0.78 | GAA (0.69) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL16727174 | 0.78 | SLC18A3 (0.55) | ALDH1A1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11400084-B2 | Aminoamide compounds | BIOTHERYX, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3508477-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20210145812-A1 | AMINOAMIDE COMPOUNDS | BIOTHERYX, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10905684-B2 | Aminoamide compounds | BIOTHERYX, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10660897-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3508477-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3078658-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100160320-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| CN-1913884-A | Substituted benzazoles and methods of their use as inhibitors of RAF kinase | CHIRON CORP (US) | 2007-02-14 | — | — | CN | disclosed |
| EP-1675584-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005032548-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | ALDH1A1 1216/4885MAPT 3948/4885MEN1 1815/4885 |
| US-20100160320-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885MAPT 4107/4885MEN1 2647/4885 |
| US-10660897-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | ALDH1A1 1216/4885MAPT 3948/4885MEN1 1815/4885 |
| US-10905684-B2 | Aminoamide compounds | DNPEP, BCAT2, AADAT | ALDH1A1 3250/4885MAPT 567/4885MEN1 1010/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885MAPT 4107/4885MEN1 2647/4885 |
| US-11400084-B2 | Aminoamide compounds | DNPEP, BCAT2, AADAT | ALDH1A1 3250/4885MAPT 567/4885MEN1 1010/4885 |
| US-20210145812-A1 | AMINOAMIDE COMPOUNDS | DNPEP, BCAT2, AADAT | ALDH1A1 3250/4885MAPT 567/4885MEN1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.